{
    "nct_id": "NCT05014412",
    "official_title": "A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA",
    "inclusion_criteria": "* Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)\n* Measurable disease, as defined by at least 1 of the following:\n\n  1. Serum M-protein >0.5 g/dL by SPEP\n  2. Urinary M-protein excretion >200 mg/24 hours by UPEP\n  3. Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio\n* Refractory to at least one IMiD\n* Refractory to at least one PI\n* Refractory to at least one anti-CD38 antibody\n* Relapsed/refractory to last anti-myeloma regimen\n* ECOG performance status ≤1\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1\n* Not pregnant and willing to use contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Smoldering multiple myeloma\n* Active Plasma cell leukemia\n* POEMS syndrome\n* Amyloidosis\n* Waldenström's macroglobulinemia\n* Known active CNS involvement or clinical signs of myelomatous meningeal involvement\n* Stem cell transplant within 12 weeks prior to enrollment or active GVHD\n* Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ or Stage 0/1 malignancy with minimal risk of recurrence per investigator.\n* Previous treatment with an anti-BCMA bispecific antibody or CAR-T cell therapy.\n* Live attenuated vaccine within 4 weeks of the first dose\n* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)\n* Known or suspected hypersensitivity to the study intervention, or any of its excipients",
    "miscellaneous_criteria": ""
}